Indegene Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Steady quarter with segmental divergence: Revenue grew sequentially, driven by recurring enterprise engagements, while shorter-tenure project segments declined, creating a mixed growth picture.
• Two pressured top accounts stabilized: Two top-five clients that previously dragged growth have stabilized, with expansion discussions underway and a recovery expected from CY 2025.
• EBITDA margin compressed 120 bps QoQ: Annual wage hikes hit margins, partially offset by productivity gains; management is striving for a full-year exit toward 20%.
• Mid-size pharma emerges as a growth lever: Clients outside the top 20 grew 10.1% sequentially, signaling adoption of the enterprise model is broadening beyond the largest life sciences firms.
• What to watch next quarter: The pace of new project kick-offs in omni-channel and consulting segments, the ramp-up of recently onboarded new logos, and any concrete FY25 margin guidance.

Revenue Performance & Segment Dynamics

• Enterprise segments anchor growth: Enterprise Commercial grew 3% sequentially and Enterprise Medical grew 4.6%, both representing recurring, long-tenure engagements with enterprise clients.
• Project-based segments dragged: Omni-channel activation and consulting segments declined as projects with 3-9 month tenures wound down and new project kick-offs lagged, causing a perturbation in overall growth.
• Top account stabilization: Two top-five customers previously flagged for downward pressure have stabilized; management expects engagements to improve from CY 2025, aligned with clients' calendar-year budgeting cycles.
• Mid-size pharma adoption broadening: Customers in the 20-30 bracket grew 10.1% sequentially, indicating the enterprise model is gaining traction beyond the top 20 life science companies.
• New logo ramp-up underway: Revenue from new logos started ramping in Q2 and is expected to continue growing in coming quarters, supporting H2 growth confidence.
• Enterprise Commercial convergence expected: The two pressured accounts impacted Enterprise Commercial almost entirely; with stabilization, management expects similar growth rates between Enterprise Commercial and Enterprise Medical going forward.

Manish Gupta: "I again want to reiterate that we are a very different business, focusing on core commercial sales and marketing, medical affairs, regulatory affairs, and clinical different functions of the global life science industry... In that context, view this in a medium to long-term perspective."

Margin Walk & Profitability

• Wage hike drove margin compression: Annual wage increments effective July 2024 caused a ~220 bps adverse impact on EBITDA, partially offset by ~100 bps from improved productivity through better capacity management and automation.
• PAT improved despite EBITDA decline: Zero interest charge following full debt repayment from IPO proceeds in June 2024, plus a small reduction in tax charge, lifted PAT to 13.4%, up 0.4% sequentially.
• EBITDA computation revised: Based on investor feedback, the company now excludes interest income from other income in EBITDA; the previously reported ~22%+ range would be approximately 2% lower on the new basis.
• Subcontracting costs stable: Other expenses, including subcontracting and freelancing for subject matter experts and regional activation roles, grew marginally in line with revenue and are not expected to change materially.
• Project segment margins under pressure: Omni-channel and consulting segments are at break-even to marginally negative at the segmental level due to overhead absorption at current scale, though contribution margins are similar to the rest of the business.

Suhas Prabhu: "we should on a full year basis, try and get towards that 20% and in the medium term I would say in the next two to three years, go even beyond that."

Client & Market Dynamics

• Top 35 pharma growth backdrop: The top 35 pharma companies are expected to grow at a 5-8% CAGR from 2025 to 2028, driven by an upsurge in drug launches.
• Upstream agency spend in play: Clients are discussing centralizing upstream activities currently handled by agencies, representing larger, more strategic spend areas for Indegene.
• Digitization model normalizing: Post-COVID normalization in sales and marketing has settled; companies are finding the right hybrid model, and conversations about agency spends as opportunities are back on the table.
• Patent cliff as tailwind: Unlike the last decade, the pipeline is strong for most companies, creating an imperative to prepare for new launches while optimizing operating models amid financial pressure from losing patents on existing drugs.
• Calendar-year budget cycle: Most customers plan October through December; the direction of discussions is stable to increasing activity as customers prepare for more products and launches into 2025 and beyond.

Manish Gupta: "the risk we see, which is always in this industry, is on timing. How quickly will they ramp up at what pace, given that, as we said earlier, this is a very cautious industry. So risk is on timing rather than whether it's going to happen or not."

Geography & Client Metrics

• Geography restated: Q1 revenue mix was restated to basis location of business origination rather than a combination with delivery or consumption locations; North America revised to 69.1% from 64.8%, Europe to 27.9% from 32.2%.
• US and EU dominance expected to hold: Management expects the revenue share from the US and Europe to remain stable at over 95%.
• Active client base expanding: Total active clients grew from 65 to 68, and USD 1 million clients grew from 36 to 37 sequentially.
• Revenue decline in Europe, medical devices, India, ROW: Correlated with omni-channel activation and consulting segments, which are more project-by-project or brand-by-brand engagements, unlike enterprise segments that cut across multiple regions and products.

Strategic Initiatives & M&A

• Cult acquisition integrated: Cult has been integrated and works alongside the enterprise; synergies are emerging between Cult and enterprise commercial solutions, combining creative, planning, medical, and global capabilities at scale.
• Large-deal pipeline incorporates Cult: The large-deal pipeline now incorporates the combined capability set from the Cult acquisition.
• M&A pipeline active: The company is actively scouting for M&A opportunities with a healthy pipeline of potential targets.
• Medium-term growth ambition: Management believes mid- to late-teens revenue growth is achievable without drastic changes, driven by deeper mining of existing customers, broadening the client base, creating a \$50M+ customer category, and tuck-in acquisitions.

Manish Gupta: "they are now thinking about how to centralize some more upstream activities, which are typically right now done by agencies. So that's the discussions we are having with a bunch of our customers, and those are much larger and, from their perspective, strategic spend areas."

Guidance & Commitments

Key Metrics